NCT03024086已完成3 期
Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia: A Multicenter, Randomized, Double-blind, Active-controlled Study (PART 1)
Daewoong Pharmaceutical Co. LTD.1 个研究点 分布在 1 个国家目标入组 124 人开始时间: 2016年12月12日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 124
- 试验地点
- 1
- 主要终点
- The change from baseline in GIS (Gastrointestinal Symptom Score)
研究概览
简要总结
The purpose of this study is to evaluate the Efficacy and Safety of DWJ1252 in treatment of Functional Dyspepsia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male of female of at least 19 years old
- •Patient with functional dyspepsia met the ROME III criteria
排除标准
- •Patients with previous gastrointestinal surgery
- •Patients with history of gastrointestinal bleeding, mechanical obstruction, perforation
- •Patients with history of gastrointestinal cancer
研究组 & 干预措施
DWJ1252
Experimental
DWJ1252 + Placebo of Gasmotin
干预措施: DWJ1252 (Drug)
Gasmotin
Active Comparator
Gasmotin + Placebo of DWJ1252
干预措施: Gasmotin (Drug)
结局指标
主要结局
The change from baseline in GIS (Gastrointestinal Symptom Score)
时间窗: At 4 Weeks
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia (PART 2)Functional DyspepsiaNCT03184402Daewoong Pharmaceutical Co. LTD.124
已完成
3 期
Clinical Study for Patients With Hypertension Associated With DyslipidemiaHypertensionDyslipidemiaNCT01764295Daewoong Pharmaceutical Co. LTD.150
Unknown
3 期
Evaluate the Efficacy and Safety of DWJ1506 and DWJ1507DyslipidemiasNCT04772443Daewoong Pharmaceutical Co. LTD.280
终止
2 期
Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the PlaceboMild to Moderate COVID-19NCT04521296Daewoong Pharmaceutical Co. LTD.432
Unknown
1 期
Pharmacokinetics and Safety Study of DWJ1392 and DWC20164 in Healthy Male VolunteersHealthyNCT03016520Daewoong Pharmaceutical Co. LTD.28